AU2018235139A1 - Compounds useful in the treatment or prevention of a PRMT5-mediated disorder - Google Patents

Compounds useful in the treatment or prevention of a PRMT5-mediated disorder Download PDF

Info

Publication number
AU2018235139A1
AU2018235139A1 AU2018235139A AU2018235139A AU2018235139A1 AU 2018235139 A1 AU2018235139 A1 AU 2018235139A1 AU 2018235139 A AU2018235139 A AU 2018235139A AU 2018235139 A AU2018235139 A AU 2018235139A AU 2018235139 A1 AU2018235139 A1 AU 2018235139A1
Authority
AU
Australia
Prior art keywords
solvate
hydrate
salt
membered heterocycloalkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018235139A
Other languages
English (en)
Inventor
Nicholas La Thangue
Rebecca Miller
Andrew Morley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argonaut Therapeutics Ltd
Original Assignee
Argonaut Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argonaut Therapeutics Ltd filed Critical Argonaut Therapeutics Ltd
Publication of AU2018235139A1 publication Critical patent/AU2018235139A1/en
Priority to AU2022202389A priority Critical patent/AU2022202389B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018235139A 2017-03-17 2018-03-16 Compounds useful in the treatment or prevention of a PRMT5-mediated disorder Abandoned AU2018235139A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022202389A AU2022202389B2 (en) 2017-03-17 2022-04-11 Compounds useful in the treatment or prevention of a PRMT5-mediated disorder

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704327.4A GB201704327D0 (en) 2017-03-17 2017-03-17 Compounds
GB1704327.4 2017-03-17
PCT/EP2018/056663 WO2018167269A1 (en) 2017-03-17 2018-03-16 Compounds useful in the treatment or prevention of a prmt5-mediated disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202389A Division AU2022202389B2 (en) 2017-03-17 2022-04-11 Compounds useful in the treatment or prevention of a PRMT5-mediated disorder

Publications (1)

Publication Number Publication Date
AU2018235139A1 true AU2018235139A1 (en) 2019-10-17

Family

ID=58688233

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018235139A Abandoned AU2018235139A1 (en) 2017-03-17 2018-03-16 Compounds useful in the treatment or prevention of a PRMT5-mediated disorder
AU2022202389A Active AU2022202389B2 (en) 2017-03-17 2022-04-11 Compounds useful in the treatment or prevention of a PRMT5-mediated disorder

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022202389A Active AU2022202389B2 (en) 2017-03-17 2022-04-11 Compounds useful in the treatment or prevention of a PRMT5-mediated disorder

Country Status (14)

Country Link
US (1) US11485731B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596061B1 (cg-RX-API-DMAC7.html)
JP (1) JP7211982B2 (cg-RX-API-DMAC7.html)
KR (1) KR102616970B1 (cg-RX-API-DMAC7.html)
CN (1) CN110650950B (cg-RX-API-DMAC7.html)
AU (2) AU2018235139A1 (cg-RX-API-DMAC7.html)
CA (1) CA3056724A1 (cg-RX-API-DMAC7.html)
GB (1) GB201704327D0 (cg-RX-API-DMAC7.html)
IL (1) IL269354B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019011061A (cg-RX-API-DMAC7.html)
NZ (1) NZ757500A (cg-RX-API-DMAC7.html)
SG (1) SG11201908598PA (cg-RX-API-DMAC7.html)
WO (1) WO2018167269A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906269B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
US11464783B2 (en) 2019-06-06 2022-10-11 Aligos Therapeutics, Inc. Heterocyclic compounds
CN110950841A (zh) * 2019-11-22 2020-04-03 济南大学 一类新型三唑类化合物的合成及应用
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
EP4076459B1 (en) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5 inhibitors
AU2021283568B2 (en) * 2020-06-02 2023-12-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd 3,4-dihydroisoquinoline compound and use thereof
BR112022025037A2 (pt) 2020-06-10 2023-02-14 Aligos Therapeutics Inc Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
CN115768769B (zh) * 2020-06-30 2024-10-22 南京再明医药有限公司 四氢异喹啉类化合物及其用途
KR102920599B1 (ko) 2020-09-04 2026-01-29 이노웨이스톤 테라퓨틱스 리미티드 항종양 활성을 갖는 화합물 및 이의 용도
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
CA3222626A1 (en) 2021-05-13 2022-11-17 Yunlong Song Compound having anti-tumor activity and use thereof
GB202108383D0 (en) * 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
AU2022404488B2 (en) * 2021-12-08 2026-04-02 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Salt of 3,4-dihydroisoquinoline compound and use thereof
WO2023125947A1 (zh) * 2021-12-30 2023-07-06 江苏先声药业有限公司 四氢异喹啉类化合物的可药用盐、晶型及其用途
WO2023131305A1 (zh) * 2022-01-06 2023-07-13 江苏先声药业有限公司 Prmt5抑制剂和抗癌治疗剂的组合
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100764A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Methods of inhibiting prmt5
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3160466A4 (en) * 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds

Also Published As

Publication number Publication date
JP7211982B2 (ja) 2023-01-24
IL269354B1 (en) 2023-07-01
EP3596061C0 (en) 2023-09-06
NZ757500A (en) 2026-03-27
MX2019011061A (es) 2019-12-19
EP3596061A1 (en) 2020-01-22
KR20190129936A (ko) 2019-11-20
US20200325128A1 (en) 2020-10-15
GB201704327D0 (en) 2017-05-03
IL269354A (en) 2019-11-28
KR102616970B1 (ko) 2023-12-22
CN110650950B (zh) 2023-09-19
BR112019019358A2 (pt) 2020-04-14
CN110650950A (zh) 2020-01-03
CA3056724A1 (en) 2018-09-20
AU2022202389A1 (en) 2022-05-05
AU2022202389B2 (en) 2024-04-18
WO2018167269A1 (en) 2018-09-20
JP2020510091A (ja) 2020-04-02
ZA201906269B (en) 2024-03-27
US11485731B2 (en) 2022-11-01
SG11201908598PA (en) 2019-10-30
EP3596061B1 (en) 2023-09-06
IL269354B2 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
EP3596061B1 (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
JP7781244B2 (ja) Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体
US11274098B2 (en) Tricyclic compounds for use in treatment of proliferative disorders
EP3630749B1 (en) 2-quinolone derived inhibitors of bcl6
RU2673079C2 (ru) Ингибиторные соединения
US10005792B2 (en) Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
JP2019508467A (ja) 癌治療用の2−シアノイソインドリン誘導体
JP2021521165A (ja) Bcl6阻害剤
AU2014400628A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
US20230183197A1 (en) Inhibitors of mlh1 and/or pms2 for cancer treatment
US20240287036A1 (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
HK40111483A (en) 2-quinolone derived inhibitors of bcl6
BR112019019358B1 (pt) Compostos, composição farmacêutica, uso dos referidos compostos, método in vitro para alterar a expressão gênica em uma célula e combinação compreendendo um composto

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted